{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:48:28Z","timestamp":1760014108643},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pupt.2014.06.002","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T00:38:48Z","timestamp":1404261528000},"page":"155-165","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Current and future therapies for invasive aspergillosis"],"prefix":"10.1016","volume":"32","author":[{"given":"Matteo","family":"Bassetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Pecori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Della Siega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pupt.2014.06.002_bib1","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1086\/323900","article-title":"The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis","volume":"33","author":"Perfect","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.pupt.2014.06.002_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-4453(96)92700-0","article-title":"Trends in the postmortem epidemiology of invasive fungal infections at a university hospital","volume":"33","author":"Groll","year":"1996","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.pupt.2014.06.002_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis","volume":"12","author":"Latge","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.pupt.2014.06.002_bib4","first-page":"545","article-title":"Macrophage-Aspergillus interactions","volume":"60","author":"Schaffner","year":"1994","journal-title":"Immunol Ser"},{"key":"10.1016\/j.pupt.2014.06.002_bib5","first-page":"57","article-title":"Host defense mechanism in Aspergillus fumigatus infections","volume":"Vol. 2","author":"Scheneemann","year":"1999"},{"issue":"6","key":"10.1016\/j.pupt.2014.06.002_bib6","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1086\/314493","article-title":"Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis","volume":"178","author":"Cenci","year":"1998","journal-title":"J Infect Dis"},{"issue":"18","key":"10.1016\/j.pupt.2014.06.002_bib7","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMra0808853","article-title":"Aspergillosis","volume":"360","author":"Segal","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pupt.2014.06.002_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1309\/UJRV9DLC11RM3G8R","article-title":"Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis","volume":"127","author":"Stergiopoulou","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"3 Suppl 6","key":"10.1016\/j.pupt.2014.06.002_bib9","first-page":"10","article-title":"Fungal infections in bone marrow transplant patients","volume":"17","author":"Meyers","year":"1990","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.pupt.2014.06.002_bib10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-007-0376-3","article-title":"Aspergillus infection in lung transplant patients: incidence and prognosis","volume":"26","author":"Iversen","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2014.06.002_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2001.tb00006.x","article-title":"Chronic forms of pulmonary aspergillosis","volume":"7","author":"Denning","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 3","key":"10.1016\/j.pupt.2014.06.002_bib12","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1086\/376526","article-title":"Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review","volume":"37","author":"Denning","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.pupt.2014.06.002_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s001340000768","article-title":"Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care?","volume":"27","author":"Bulpa","year":"2001","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.pupt.2014.06.002_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"De\ufb01ning opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib16","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.pupt.2014.06.002_bib17","article-title":"Approach to invasive pulmonary aspergillosis in critically ill patients","volume":"27","author":"Koulenti","year":"2014","journal-title":"Current opinion inf dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jhep.2013.09.011","article-title":"Invasive aspergillosis in patients withsevere alcoholic hepatitis","volume":"60","author":"Gustot","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.pupt.2014.06.002_bib19","first-page":"173","article-title":"Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patients","volume":"26","author":"Garnacho-Montero","year":"2013","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.pupt.2014.06.002_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"Meersseman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1179\/acb.2004.037","article-title":"Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality","volume":"59","author":"Vandewoude","year":"2004","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.pupt.2014.06.002_bib22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1164\/rccm.201111-1978OC","article-title":"A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients","volume":"186","author":"Blot","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/2049-6958-8-59","article-title":"Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease","volume":"8","author":"Tutar","year":"2013","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jinf.2012.07.006","article-title":"Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by GOLD stage","volume":"65","author":"Barberan","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.pupt.2014.06.002_bib25","first-page":"2973","article-title":"Significance of Aspergillus spp. isolation from lower respiratory tract samples for the diagnosis and prognosis of invasive pulmonary aspergillosis in chronic obstructive pulmonary disease","volume":"125","author":"He","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pupt.2014.06.002_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1469-0691.2011.03503.x","article-title":"Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China","volume":"18","author":"Xu","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pupt.2014.06.002_bib27","series-title":"Annual update in intensive care and emergency medicine","first-page":"63","article-title":"Invasive pulmonary aspergillosis in critically ill patients","author":"Blot","year":"2013"},{"key":"10.1016\/j.pupt.2014.06.002_bib28","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1469-0691.2009.03015.x","article-title":"Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome","volume":"16","author":"Guinea","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pupt.2014.06.002_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1086\/518852","article-title":"Invasive aspergillosis in the intensive care unit","volume":"45","author":"Meersseman","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.pupt.2014.06.002_bib30","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc4823","article-title":"Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients","volume":"10","author":"Vandewoude","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.pupt.2014.06.002_bib31","first-page":"1396","article-title":"Fungal sepsis in the ICU: are we doing better? \u2013 Trends in incidence, diagnosis, and outcome","volume":"79","author":"Blot","year":"2013","journal-title":"Minerva Anestesiol"},{"key":"10.1016\/j.pupt.2014.06.002_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1440-1843.2012.02283.x","article-title":"Invasive pulmonary aspergillosis in nonneutropenic patients with and without underlying disease: a single-centre retrospective analysis of 52 subjects","volume":"18","author":"Dai","year":"2013","journal-title":"Respirology"},{"issue":"12","key":"10.1016\/j.pupt.2014.06.002_bib33","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.7150\/ijms.6824","article-title":"Risk Factors for Invasive Pulmonary Aspergillosis and Hospital Mortality in Acute-On-Chronic Liver Failure Patients: A Retrospective-Cohort Study","volume":"10","author":"Chen","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.pupt.2014.06.002_bib34","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jhin.2006.02.014","article-title":"Nosocomial aspergillosis in outbreak settings","volume":"63","author":"Vonberg","year":"2006","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.pupt.2014.06.002_bib35","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/myc.12070","article-title":"The indoor air as a potential determinant of the frequency of invasive aspergillosis in the intensive care","volume":"56","author":"Boff","year":"2013","journal-title":"Mycoses"},{"issue":"3","key":"10.1016\/j.pupt.2014.06.002_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.pupt.2014.06.002_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0954-6111(06)80062-4","article-title":"The value of bronchoalveolar lavage and bronchial washings in the diagnosis of invasive pulmonary aspergillosis","volume":"86","author":"Levy","year":"1992","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.pupt.2014.06.002_bib38","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/516480","article-title":"Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation","volume":"175","author":"Wald","year":"1997","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.pupt.2014.06.002_bib39","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1309\/EXBVYAUPENBM285Y","article-title":"Diagnosis of invasive septate mold infections: a correlation of microbiological culture and histologic or cytologic examination","volume":"119","author":"Tarrand","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pupt.2014.06.002_bib40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0065-2164(10)70006-X","article-title":"Detection of invasive aspergillosis","volume":"70","author":"Thornton","year":"2010","journal-title":"Adv Appl Microbiol"},{"issue":"10","key":"10.1016\/j.pupt.2014.06.002_bib41","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MCP.0b013e3283447b60","article-title":"Antigen detection in bronchoalveolar lavage fluid for diagnosis of fungal pneumonia","volume":"17","author":"Hage","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1378\/chest.10-0488","article-title":"Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review","volume":"138","author":"Guo","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.pupt.2014.06.002_bib44","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.amjmed.2011.10.008","article-title":"Invasive mycoses: diagnostic challenges","volume":"125","author":"Ostrosky-Zeichner","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib45","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1086\/527382","article-title":"1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia","volume":"46","author":"Senn","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib46","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1128\/JCM.02091-07","article-title":"Contribution of the (1-->3)-beta-D-glucan assay for diagnosis of invasive fungal infections","volume":"46","author":"Persat","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pupt.2014.06.002_bib47","first-page":"553","article-title":"Evaluation of plasma (1-->3)-beta-D-glucan measurement by the kinetic turbidimetric Limulus test, for the clinical diagnosis of mycotic infections","volume":"35","author":"Mori","year":"1997","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1016\/j.pupt.2014.06.002_bib48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/cid\/cir897","article-title":"\u03b2-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3)","volume":"54","author":"Lamoth","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib49","doi-asserted-by":"crossref","first-page":"R249","DOI":"10.1186\/cc10507","article-title":"Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1\u21923)-\u03b2-D-glucan assay, Candida score, and colonization index","volume":"15","author":"Posteraro","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.pupt.2014.06.002_bib50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1185\/03007995.2012.761134","article-title":"Fungal diagnosis: how do we do it and can we do better?","volume":"29","author":"Perfect","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pupt.2014.06.002_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/jcp.2008.058354","article-title":"Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients","volume":"62","author":"Barnes","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.pupt.2014.06.002_bib52","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1128\/JCM.03189-12","article-title":"Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis","volume":"51","author":"White","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.pupt.2014.06.002_bib53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s003300050386","article-title":"Aspergillus infection of the respiratory tract after lung transplantation: chest radiographic and CT findings","volume":"8","author":"Diederich","year":"1998","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.pupt.2014.06.002_bib54","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-2007-1015487","article-title":"The typical radiological findings and course of invasive pulmonary aspergillosis in the immunosuppressed patient","volume":"167","author":"Leutner","year":"1997","journal-title":"Rofo"},{"issue":"3","key":"10.1016\/j.pupt.2014.06.002_bib55","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1034\/j.1600-0455.2002.430310.x","article-title":"Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis","volume":"43","author":"Hauggaard","year":"2002","journal-title":"Acta Radiol"},{"issue":"3","key":"10.1016\/j.pupt.2014.06.002_bib56","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib57","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1086\/518387","article-title":"Halo sign and improved outcome","volume":"44","author":"Verweij","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.pupt.2014.06.002_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jac\/dkq438","article-title":"Detection and investigation of invasive mould disease","volume":"66","author":"Cuenca-Estrella","year":"2011","journal-title":"J Antimicrob Chemoter"},{"key":"10.1016\/j.pupt.2014.06.002_bib59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09059180.00001011","article-title":"Pulmonary aspergillosis: a clinical review","volume":"20","author":"Kousha","year":"2011","journal-title":"Eur Respir Rev"},{"issue":"9","key":"10.1016\/j.pupt.2014.06.002_bib60","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/cid\/cir122","article-title":"The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts","volume":"52","author":"Georgiadou","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/505870","article-title":"Comparison of epidemiological, clinical and biological features of invasive aspergillosis in neutropenic and non-neutropenic patients: a 6-year survey","volume":"43","author":"Cornillet","year":"2006","journal-title":"Clin Infec Dis"},{"issue":"18","key":"10.1016\/j.pupt.2014.06.002_bib62","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Fl\u00f6rl","year":"2011","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.pupt.2014.06.002_bib63","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0031-1295715","article-title":"Pulmonary aspergillosis: recent advances","volume":"32","author":"Thompson","year":"2011","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib64","series-title":"Asbtracts of Advances against Aspergillosis, 9\u201311 September, San Francisco, CA","article-title":"Aspergillus in vitro antifungal data: new millennium trends","author":"Sutton","year":"2004"},{"issue":"3","key":"10.1016\/j.pupt.2014.06.002_bib65","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/EC.4.3.625-632.2005","article-title":"Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus","volume":"4","author":"Balajee","year":"2005","journal-title":"Eukaryot Cell"},{"issue":"4","key":"10.1016\/j.pupt.2014.06.002_bib66","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1128\/AAC.48.4.1197-1203.2004","article-title":"Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals","volume":"48","author":"Balajee","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.pupt.2014.06.002_bib67","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.pupt.2014.06.002_bib68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.pupt.2014.06.002_bib69","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/jac\/dku009","article-title":"A Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients","volume":"69","author":"J1","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.pupt.2014.06.002_bib70","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1128\/JCM.03182-13","volume":"52","author":"Rocchi","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pupt.2014.06.002_bib71","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib72","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib73","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pupt.2014.06.002_bib74","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00134-009-1546-9","article-title":"Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report","volume":"35","author":"De Rosa","year":"2009","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.pupt.2014.06.002_bib75","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000069281","article-title":"Intravenous itracolnazole follone by oral itraconazole for the treatment of amphotericin B-refractory invasive pulmonary aspergillosis","volume":"109","author":"Caillot","year":"2003","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.pupt.2014.06.002_bib76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","article-title":"NIAID Mycoses study group Multicenter trial of oral itraconazole therapy for invasive aspergillosis","volume":"97","author":"Denning","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib77","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1086\/507891","article-title":"New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage","volume":"43","author":"Spanakis","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib78","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1056\/NEJM200212193472518","article-title":"Voriconazole versus Amphotericin B for invasive aspergillosis","volume":"347","author":"Blot","year":"2002","journal-title":"N EnGL J Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib79","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1056\/NEJM200212193472518","article-title":"Voriconazole versus amphotericin B Voriconazole versus Amphotericin B for invasive aspergillosis","volume":"347","author":"Karthaus","year":"2002","journal-title":"N EnGL J Med"},{"issue":"4","key":"10.1016\/j.pupt.2014.06.002_bib80","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.pupt.2014.06.002_bib82","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.01807-09","article-title":"Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma","volume":"54","author":"Baietto","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib83","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/423274","article-title":"Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole","volume":"39","author":"Imhof","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.pupt.2014.06.002_bib84","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib85","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib86","first-page":"6","article-title":"Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles","author":"Dellacasa","year":"2013","journal-title":"J Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib87","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib88","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pupt.2014.06.002_bib89","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1128\/AAC.00815-12","article-title":"Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease","volume":"56","author":"Tonini","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2014.06.002_bib90","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib91","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib92","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/JCM.01155-09","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pupt.2014.06.002_bib93","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib94","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.pupt.2014.06.002_bib95","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib96","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s10156-011-0219-0","article-title":"Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report","volume":"17","author":"Hanadate","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib97","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10096-012-1754-z","article-title":"A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis","volume":"32","author":"Kohno","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib98","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/AAC.46.9.3039-3041.2002","article-title":"In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp","volume":"46","author":"Perea","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib99","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.46.8.2564-2568.2002","article-title":"Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis","volume":"46","author":"Kirkpatrick","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib101","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.pupt.2014.06.002_bib102","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.11115","article-title":"Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin","volume":"97","author":"Aliff","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.pupt.2014.06.002_bib103","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cncr.11479","article-title":"Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies","volume":"98","author":"Kontoyiannis","year":"2003","journal-title":"Cancer"},{"year":"2012","author":"Marr","series-title":"A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis","key":"10.1016\/j.pupt.2014.06.002_bib104"},{"key":"10.1016\/j.pupt.2014.06.002_bib105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/jac\/dks402","article-title":"Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis","volume":"68","author":"Seyedmousavi","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib106","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring: A Multi-Center Study","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib107","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jac\/dkh022","article-title":"Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation","volume":"53","author":"Groll","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib108","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-007-0350-0","article-title":"Voriconazole and fluconazole increase the exposure to oral diazepam","volume":"63","author":"Saari","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pupt.2014.06.002_bib109","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","article-title":"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"79","author":"Saari","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pupt.2014.06.002_bib110","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00228-008-0568-5","article-title":"Voriconazole drastically increases exposure to oral oxycodone","volume":"65","author":"Hagelberg","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pupt.2014.06.002_bib111","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00228-010-0969-0","article-title":"Interaction of oxycodone and voriconazole-a case series of patients with cancer pain supports the findings of randomised controlled studies with healthy subjects","volume":"67","author":"Hagelberg","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pupt.2014.06.002_bib112","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00228-010-0968-1","article-title":"Effects of voriconazole co-administration on oxycodone-induced adverse events: a case in the retrospective survey","volume":"67","author":"Watanabe","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.pupt.2014.06.002_bib113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00228-007-0398-x","article-title":"Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl","volume":"64","author":"Saari","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"year":"2012","author":"Vfend (voriconazole)","series-title":"EMA summary of product characteristics","key":"10.1016\/j.pupt.2014.06.002_bib114"},{"key":"10.1016\/j.pupt.2014.06.002_bib115","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/bjo.2007.136515","article-title":"Voriconazole in the treatment of fungal eye infections: a review of current literature","volume":"92","author":"Hariprasad","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.pupt.2014.06.002_bib116","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1086\/377131","article-title":"Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients","volume":"37","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib117","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib118","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib119","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.00957-06","article-title":"Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods","volume":"51","author":"Pascual","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0b013e31823f3516","article-title":"Therapeutic drug monitoring of voriconazole in children","volume":"34","author":"Chen","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pupt.2014.06.002_bib121","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.05219-11","article-title":"Observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels and associations, Bhama JK: A prospective, between serum troughs, efficacy and toxicity","volume":"56","author":"Mitsani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib122","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1592\/phco.31.2.214","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole","volume":"31","author":"Hussaini","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pupt.2014.06.002_bib123","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib124","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","article-title":"Voriconazole in clinical practice","volume":"24","author":"Mikulska","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib125","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","article-title":"Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"35","author":"Trifilio","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.pupt.2014.06.002_bib126","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1128\/AAC.01316-08","article-title":"Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation","volume":"53","author":"Trifilio","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib127","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.pupt.2014.06.002_bib128","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/pbc.22451","article-title":"Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age","volume":"54","author":"Shima","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.pupt.2014.06.002_bib129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2014.06.002_bib130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/INF.0b013e318204d227","article-title":"Impact of therapeutic drug monitoring of voriconazole in a pediatric population","volume":"30","author":"Bruggemann","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.pupt.2014.06.002_bib131","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.pupt.2014.06.002_bib132","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/jac\/dks285","article-title":"Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS","volume":"67","author":"Baietto","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib133","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2014.06.002_bib134","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.pupt.2014.06.002_bib135","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/2049-6958-9-23","article-title":"Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review","volume":"9","author":"D Amato","year":"2014","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.pupt.2014.06.002_bib136","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/thx.2010.153312","article-title":"Effects of omalizumab in Aspergillus-associated airway disease","volume":"66","author":"P\u00e9rez-de-Llano","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2014.06.002_bib137","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1398-9995.2011.02599.x","article-title":"Allergic bronchopulmonary aspergillosis and omalizumab","volume":"66","author":"Tillie-Leblon","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2014.06.002_bib138","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1749-6632.2012.06810.x","article-title":"The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis","volume":"1272","author":"Moss","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pupt.2014.06.002_bib139","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1172\/JCI42388","article-title":"Vitamin D3 attenuates Th2 reponses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis","volume":"120","author":"Kreindler","year":"2010","journal-title":"J Clin Invest"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553914000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T21:25:12Z","timestamp":1598045112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553914000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":139,"alternative-id":["S1094553914000686"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2014.06.002","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future therapies for invasive aspergillosis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2014.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}